HALO vs. EXEL, RGEN, NVAX, RLAY, ADPT, ALLO, FATE, KOD, NBIX, and RVMD
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Exelixis (EXEL), Repligen (RGEN), Novavax (NVAX), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Neurocrine Biosciences (NBIX), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry.
Exelixis (NASDAQ:EXEL) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.
85.3% of Exelixis shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.9% of Exelixis shares are held by company insiders. Comparatively, 2.7% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Exelixis currently has a consensus target price of $26.13, indicating a potential upside of 28.44%. Halozyme Therapeutics has a consensus target price of $53.14, indicating a potential upside of 23.36%. Given Halozyme Therapeutics' higher probable upside, research analysts clearly believe Exelixis is more favorable than Halozyme Therapeutics.
Halozyme Therapeutics has a net margin of 36.94% compared to Halozyme Therapeutics' net margin of 11.10%. Exelixis' return on equity of 225.71% beat Halozyme Therapeutics' return on equity.
In the previous week, Exelixis had 2 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 14 mentions for Exelixis and 12 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.94 beat Exelixis' score of 0.62 indicating that Exelixis is being referred to more favorably in the media.
Exelixis has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Exelixis received 74 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.19% of users gave Halozyme Therapeutics an outperform vote while only 68.12% of users gave Exelixis an outperform vote.
Halozyme Therapeutics has lower revenue, but higher earnings than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
Summary
Halozyme Therapeutics beats Exelixis on 10 of the 18 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
